Lenvatinib/Pembrolizumab Combo Shows Promise in Thymic Epithelial Tumors
Lenvatinib plus pembrolizumab showed 88.4% 5-month PFS in platinum-refractory advanced B3-thymoma and thymic carcinoma, with median PFS of 14.9 months. The combination outperformed monotherapies, suggesting it could be a new standard treatment. Subgroup analyses indicated benefits regardless of age, gender, or histologic subtype, but significant benefits were seen in patients without liver metastases and those without lenvatinib dose reduction. Grade 3 or higher AEs occurred in 46.5% of patients, emphasizing the need for close monitoring.
Related Clinical Trials
Reference News
Lenvatinib plus pembrolizumab showed 88.4% 5-month PFS in platinum-refractory advanced B3-thymoma and thymic carcinoma, with median PFS of 14.9 months. The combination outperformed monotherapies, suggesting it could be a new standard treatment. Subgroup analyses indicated benefits regardless of age, gender, or histologic subtype, but significant benefits were seen in patients without liver metastases and those without lenvatinib dose reduction. Grade 3 or higher AEs occurred in 46.5% of patients, emphasizing the need for close monitoring.